Bio-Rad Laboratories, Inc. v. 10X Genomics Inc.

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: RainDance Technologies, Inc. (Delaware) and The University of Chicago (Illinois)
  • Defendant: 10X Genomics, Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:15-cv-00152, D. Del., 10/21/2016
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because both the lead Plaintiff (RainDance) and the Defendant (10X Genomics) are incorporated in Delaware.
• Core Dispute: Plaintiffs allege that Defendant's microfluidic genetic analysis platforms and associated reagents infringe six U.S. patents related to methods and devices for forming and manipulating discrete fluid droplets for biochemical reactions.
• Technical Context: The technology involves microfluidics, a field focused on manipulating picoliter-to-nanoliter volumes of fluids to perform high-throughput biochemical analysis, such as DNA sequencing, which is critical for genomics, disease research, and diagnostics.
• Key Procedural History: The operative pleading is a Third Amended Complaint. The complaint alleges that Defendant 10X Genomics continued its infringing activities despite having pre-suit knowledge of the patents-in-suit and after the original complaint was filed on February 12, 2015. The complaint also notes that Defendant's efforts to invalidate U.S. Patent No. 7,129,091 via inter partes review were unsuccessful.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,129,091 - "Device and Method for Pressure-Driven Plug Transport and Reaction," Issued October 31, 2006

The Invention Explained

• Problem Addressed: The patent's background describes limitations of then-current microfluidic systems. Pressure-driven flows suffer from high sample dispersion (known as Taylor dispersion), which dilutes samples and causes cross-contamination, while electro-osmotic flow (EOF) systems are slow and highly sensitive to the surface chemistry of the microfluidic channels '091 Patent, col. 1:53-2:6
• The Patented Solution: The invention uses two immiscible fluids: a sample-containing "plug-fluid" and a "carrier-fluid" (e.g., oil). By introducing the plug-fluid into a flowing stream of the carrier-fluid, the system creates discrete, isolated "plugs" (droplets) that encapsulate the sample '091 Patent, abstract These plugs are transported by pressure with minimal dispersion because the carrier-fluid insulates them from the channel walls, and mixing within the plugs is enhanced through chaotic advection created by winding channels '091 Patent, col. 3:5-11 '091 Patent, Fig. 3A
• Technical Importance: This approach provided a method to conduct high-speed, low-volume, precisely controlled reactions by combining the robustness of pressure-driven systems with the low-dispersion characteristics of plug-based transport '091 Patent, col. 1:19-24

Key Claims at a Glance

• The complaint asserts independent claim 1 and a number of its dependent claims Compl. ¶31
• The essential elements of independent claim 1, a method claim, are:
  • Introducing a carrier-fluid into a first channel of a substrate.
  • Introducing at least two different plug-fluids into the first channel.
  • Applying pressure to induce flow and form substantially identical plugs comprising a mixture of the plug-fluids.
  • The plug-fluids are immiscible with the carrier-fluid.
  • The plug's cross-section during formation is substantially similar to the channel's cross-section.
• The complaint does not explicitly reserve the right to assert other dependent claims for this patent.

U.S. Patent No. 8,304,193 - "Method for Conducting an Autocatalytic Reaction in Plugs in a Microfluidic System," Issued November 6, 2012

The Invention Explained

• Problem Addressed: Autocatalytic reactions, where a product of a reaction catalyzes the reaction itself, can be unstable and difficult to control, particularly in bulk or in continuous-flow systems where a reaction can propagate uncontrollably '193 Patent, col. 11:42-50 '193 Patent, col. 35:50-36:31
• The Patented Solution: The invention uses the plug-based microfluidic system to compartmentalize autocatalytic reactions within discrete, isolated plugs. This containment prevents unwanted propagation of the reaction throughout the system and allows for the controlled amplification of a chemical signal within each individual plug '193 Patent, col. 12:40-55 '193 Patent, Fig. 37
• Technical Importance: This method enables the use of unstable but highly sensitive autocatalytic reactions for applications like high-throughput screening and diagnostics, where a very small amount of a target molecule can trigger a large, easily detectable signal within a contained droplet.

Key Claims at a Glance

• The complaint asserts independent claims 1 and 11, along with dependent claims 2-8 Compl. ¶45
• The complaint does not provide the claim text for analysis.

U.S. Patent No. 8,329,407 - "Method for Conducting Reactions Involving Biological Molecules in Plugs in a Microfluidic System," issued December 11, 2012

• Patent Identification: U.S. Patent No. 8,329,407, "Method for Conducting Reactions Involving Biological Molecules in Plugs in a Microfluidic System," issued December 11, 2012 Compl. ¶56
• Technology Synopsis: The patent describes a method for performing reactions with biological molecules, such as DNA or RNA, within the discrete plugs of a microfluidic system. This adapts the general plug-transport method to the specific requirements of biochemical assays, such as polymerase chain reaction (PCR) or enzymatic reactions '407 Patent, col. 10:1-13 '407 Patent, abstract
• Asserted Claims: Claims 1-5, 8-11, and 13 Compl. ¶59
• Accused Features: The complaint alleges that the GemCode platform, when used to partition and amplify nucleic acids in droplets, infringes this patent Compl. ¶59

U.S. Patent No. 8,822,148 - "Method of Performing PCR Reaction in Continuously Flowing Microfluidic Plugs," issued September 2, 2014

• Patent Identification: U.S. Patent No. 8,822,148, "Method of Performing PCR Reaction in Continuously Flowing Microfluidic Plugs," issued September 2, 2014 Compl. ¶70
• Technology Synopsis: This patent details a method specifically for performing PCR within flowing microfluidic plugs. The method involves providing the necessary reagents for PCR within the plugs and subjecting them to thermal cycling to amplify DNA or RNA '148 Patent, col. 1:1-2:2 '148 Patent, abstract
• Asserted Claims: Claims 1-3 and 6-8 Compl. ¶73
• Accused Features: The complaint alleges that the GemCode platform's process of amplifying DNA within droplets via thermocycling infringes this patent Compl. ¶19 Compl. ¶73

U.S. Patent No. 8,889,083 - "Device and Method for Pressure-Driven Plug Transport and Reaction," issued November 18, 2014

• Patent Identification: U.S. Patent No. 8,889,083, "Device and Method for Pressure-Driven Plug Transport and Reaction," issued November 18, 2014 Compl. ¶84
• Technology Synopsis: This patent, like the '091 patent, covers both the microfluidic device and the method for transporting reactants in discrete plugs using an immiscible carrier fluid. The claims appear to cover both the apparatus itself (a device with specified channels and inlets) and the method of its use to form and transport plugs for conducting a reaction '083 Patent, abstract '083 Patent, claim 1 '083 Patent, claim 20
• Asserted Claims: Claims 1-2, 10-13, 20-22, 26, and 31 Compl. ¶87
• Accused Features: The complaint alleges infringement by the making, selling, and/or using of the GemCode platform, which is accused of being an infringing apparatus and of performing an infringing method Compl. ¶87

U.S. Patent No. 8,658,430 - "Manipulating Droplet Size," issued February 25, 2014

• Patent Identification: U.S. Patent No. 8,658,430, "Manipulating Droplet Size," issued February 25, 2014 Compl. ¶99
• Technology Synopsis: This patent discloses methods for controlling the size of droplets in a microfluidic system. The invention involves adjusting the pressure exerted on the aqueous fluid or the carrier fluid during droplet formation, allowing for independent control of droplet size in multiple parallel circuits '430 Patent, col. 1:12-16 '430 Patent, col. 2:15-24
• Asserted Claims: Claims 1, 5, and 12-16 Compl. ¶101
• Accused Features: The complaint alleges that the use of the GemCode platform to form droplets infringes this patent Compl. ¶101

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are Defendant's "GemCode platform" and its upgraded version, the "Chromium Controller," along with their associated "GemCode Reagents" and Chromium reagent kits (Compl. ¶15, Compl. ¶21; Compl. ¶22; Compl. ¶23).

Functionality and Market Context

• The complaint alleges the accused products are microfluidic systems that partition nucleic acid samples, such as DNA, into hundreds of thousands or millions of nanoliter-scale aqueous droplets suspended in an immiscible oil Compl. ¶12 Compl. ¶21 The schematic provided in the complaint shows that gel beads loaded with barcoded oligonucleotides are mixed with a sample and enzyme mixture, then combined with an oil-surfactant solution at a 'double-cross' junction to form "Gel bead-containing droplets (GEMs)" Compl. ¶21 The complaint describes that within each droplet, an enzymatic amplification reaction occurs, and the barcode from the gel bead attaches to the amplified DNA fragments Compl. ¶12 Compl. ¶19 This process allegedly creates "libraries" of barcoded DNA molecules for sequencing, where all fragments from a single original DNA molecule (or cell) share a common barcode Compl. ¶13
• A schematic from a 10X presentation shows the process of "Solid phase reagent delivery," "Fluid partitioning," and "Liquid phase biochemistry" occurring in a microfluidic channel Compl. ¶16 The complaint positions these products as direct competitors to Plaintiffs' own microfluidic systems, operating in the "emerging field" of genetic analysis Compl. ¶12 The instruments are alleged to be priced from $75,000 to $125,000 Compl. ¶14 Compl. ¶21

IV. Analysis of Infringement Allegations

The complaint alleges infringement of six patents but incorporates by reference preliminary claim charts (Exhibits 17-22) that are not attached to the pleading Compl. ¶26 Therefore, the narrative infringement theories are summarized below in prose.

• '091 and '083 Patent Infringement Allegations: The complaint alleges that the use of the GemCode and Chromium platforms directly infringes method claims related to forming and reacting materials in microfluidic plugs Compl. ¶31 Compl. ¶87 The alleged infringing process involves introducing a carrier-fluid (oil) and at least two separate "plug-fluids" (a DNA/reagent mixture and a gel bead slurry) into a microchannel under pressure to form discrete droplets (plugs) where a reaction occurs (Compl. ¶16, Compl. ¶18, Compl. ¶20). The complaint further alleges that the GemCode platform itself is an infringing apparatus under the '083 patent Compl. ¶87 The complaint includes a diagram from a 10X Genomics article in Nature Biotechnology illustrating the 'double-cross' junction for droplet generation and subsequent processing steps (Compl. ¶20).
• '193 and '407 Patent Infringement Allegations: The complaint alleges that when customers use the GemCode platform for DNA amplification, they infringe method claims for conducting autocatalytic reactions and reactions with biological molecules in plugs Compl. ¶45 Compl. ¶59 The amplification process within the droplets, such as PCR, is alleged to be an autocatalytic reaction involving biological molecules (DNA, enzymes), thereby practicing the claimed methods Compl. ¶19 A visual from a 10X presentation shows a "Cycle" step occurring after droplet collection, which the complaint alleges corresponds to the claimed reaction Compl. ¶16 Compl. ¶19
• '148 Patent Infringement Allegations: The complaint alleges infringement of method claims for performing a PCR reaction in continuously flowing microfluidic plugs Compl. ¶73 The complaint describes that after the droplets are formed and collected, they are placed on a thermal cycler to perform amplification, which allegedly constitutes the claimed method Compl. ¶19
• '430 Patent Infringement Allegations: The complaint alleges infringement of method claims for manipulating droplet size Compl. ¶101 The infringement theory appears to be based on the operation of the GemCode and Chromium systems to generate the droplets themselves, a process which inherently involves controlling their size. The complaint does not provide specific narrative detail on how the accused method of droplet size manipulation maps to the claims.
• Identified Points of Contention:
  • Scope Questions: A primary question may be whether the introduction of a slurry of "barcoded gel beads" and a separate liquid mixture of "biochemical reagents with their DNA" Compl. ¶18 constitutes the introduction of "at least two different plug-fluids" as required by claim 1 of the '091 patent. The construction of "plug-fluid" may be central to this issue.
  • Technical Questions: The infringement allegation for the '193 patent hinges on the DNA amplification reaction being "autocatalytic" Compl. ¶45 A potential point of contention may be whether a templated amplification process like PCR meets the technical and legal definition of an "autocatalytic reaction" as contemplated by the patent.

V. Key Claim Terms for Construction

• The Term: "plug-fluids" (from '091 Patent, claim 1)

  • Context and Importance: Claim 1 of the '091 patent requires introducing "at least two different plug-fluids." The accused system is alleged to introduce a slurry of gel beads and a separate liquid sample Compl. ¶18 Practitioners may focus on whether a slurry of semi-solid gel beads qualifies as a "plug-fluid," a term whose definition will be critical to the infringement analysis.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent defines "plug-fluid" as "a fluid wherein or using which a reaction or precipitation can occur," which "may contain a solvent and a reagent" that "may be soluble or insoluble" '091 Patent, col. 9:61-64 This language could support an interpretation that includes suspensions or slurries of insoluble components.
    • Evidence for a Narrower Interpretation: The specification frequently describes the "plug-fluids" as "streams," "solutions," or "liquids" that form "laminar streams" before being segmented into plugs '091 Patent, col. 17:50-55 '091 Patent, Fig. 2A This context may support an argument that the term is limited to liquids and excludes slurries of solid beads.

• The Term: "substantially identical plugs" (from '091 Patent, claim 1)

  • Context and Importance: The claim requires the formation of "substantially identical plugs." The functionality of the accused sequencing technology relies on generating a massive number of discrete droplets for parallel reactions. The degree of uniformity required by "substantially identical" will be a key issue in determining whether the output of the accused system meets this limitation.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent's objective is to provide a method that avoids the high dispersion of continuous pressure-driven flow '091 Patent, col. 1:53-65 This purpose may suggest that "substantially identical" only requires sufficient uniformity to prevent random coalescence and ensure discrete transport, not perfect monodispersity.
    • Evidence for a Narrower Interpretation: The patent abstract states the method forms plugs that are "substantially similar in size," and figures such as 3A and 3B depict highly regular, monodisperse plugs. A defendant could argue this establishes a high standard of uniformity that the accused device may not meet in practice.

VI. Other Allegations

• Indirect Infringement: The complaint alleges induced infringement, stating that 10X provides promotional materials, product brochures, and instructional materials that encourage and instruct customers to use the accused platforms in an infringing manner Compl. ¶¶33-37 It is also alleged that 10X created distribution and co-marketing relationships with companies like Illumina and Qiagen with the specific intent that customers would use the platform to infringe Compl. ¶35 Contributory infringement is alleged on the basis that the accused platforms and their components are specialized, constitute a material part of the inventions, and are not staple articles of commerce with substantial non-infringing uses Compl. ¶¶38-39
• Willful Infringement: The complaint alleges willful infringement based on pre-suit knowledge. It asserts that 10X's CEO, COO, and CSO acknowledged having knowledge of the '091 patent since at least April 18, 2013, nearly two years before the original complaint was filed Compl. ¶32 Willfulness is further alleged based on 10X's continued infringement after the lawsuit was filed and after its failed attempts to invalidate the '091 patent in inter partes review proceedings Compl. ¶40

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of definitional scope: can the term "plug-fluid," which the '091 patent describes as a fluid in which a reaction can occur, be construed to cover the slurry of solid or semi-solid barcoded gel beads used in the accused systems? The outcome of this claim construction question may significantly impact the infringement analysis for a large portion of the asserted patent portfolio.
• A second central question will be one of technical classification: does the templated DNA amplification performed within the accused droplets (e.g., PCR) qualify as an "autocatalytic reaction" under the meaning of the '193 patent claims? This will require the court to analyze the specific technical nature of both the claimed invention and the accused process.
• A third key issue, pertinent to damages, will be willfulness: given the complaint's specific allegations of pre-suit knowledge by 10X's top executives and continued infringement after a failed IPR challenge, the court will likely need to determine whether the alleged infringement, if found, was egregious and warrants enhanced damages.